Acyclovir suppressive therapy

Effect of Long-Term, Low-Dose Acyclovir Suppressive Therapy on Susceptibility to Acyclovir and Frequency of Acyclovir Resistance of Herpes Simplex Virus Type 2

We use acyclovir 400 mg three times daily as suppressive therapy. Doses for suppressive therapy are higher in pregnant compared with nonpregnant women because

Acyclovir, famciclovir, and valacyclovir are effective at shortening the duration and severity of an outbreak. Daily suppressive therapy

cy of acyclovir-resistance of the virus population isolated directly from lesions of genital herpes. This finding suggests that long-term, low-dose acyclovir suppressive therapy for Antiviral Chemistry Chemotherapy 3 239 Effect of long-term, low-dose acyclovir suppressive therapy on susceptibility to acyclovir and frequency of

first recurrence of symptoms in favor of suppressive dosing (P 0.0001). Suppressive therapy with oral acyclovir, famciclovir or valacyclovir

acyclovir-suppressive therapy. Thus, the low dose of acyclovir suppressive therapy did not affect the susceptibility to acyclovir or increase the fre-quency of acyclovir-resistant viruses in the geni-tal lesions. Keywords: genital herpes, herpes simplex virus, acyclovir, susceptibility Introduction 2024 International Medical Press

tions such as acyclovir, valacyclovir, and famciclovir can mitigate EPISODIC THERAPY VS CHRONIC SUPPRESSIVE. THERAPY. Episodic

cy of acyclovir-resistance of the virus population isolated directly from lesions of genital herpes. This finding suggests that long-term, low-dose acyclovir suppressive therapy for Antiviral Chemistry Chemotherapy 3 239 Effect of long-term, low-dose acyclovir suppressive therapy on susceptibility to acyclovir and frequency of

by DF Kimberlin 2024 Cited by 96receiving herpes simplex virus suppressive therapy with the acyclovir prodrug valacyclovir. Both valacyclovir and acyclovir daily suppressive ther- apy have